probiotics

From supplements to drug development: how Biogaia navigates both worlds

Nigel Titford, CEO at Biogaia Pharma, discusses the strategic considerations and challenges involved in working across both the dietary supplement and pharmaceutical sectors. 

Flow VIT® Test Kits: The Next Step in Specific Probiotic Enumeration

In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.

Probiotic intervention in the gut–prostate axis with novaPROX combo: insights from an in vitro study

The study published on Foods Journal researched the mechanisms of action of Probionova's novaPROX product using a 3D intestinal barrier model and a co-culture prostatic model.

The evolution of REBYOTA: milestones in microbiome-based therapeutics

On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.

Innovative Potential of Lonza’s Capsugel® Enprotect® Capsules in Targeted Live Biotherapeutics and Pharmaceutical Applications

Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.

Unlocking the hidden world of the small intestine: a new frontier in microbiome science

Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.

Gut to lung: how a new Akkermansia muciniphila strain is reshaping respiratory health

Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.

Optimizing iron supplementation with prebiotics: addressing deficiency and gut health

Raphaëlle Bourdet-Sicard from Danone Nutricia Research discusses a study which investigates the use of a mixed prebiotic formulation to enhance iron  absorption while mitigating adverse effects on gut microbiota. 

Study links gut bacteria to Alzheimer’s, uncovering potential new targets

The findings suggest that gut microbes and LPC are potential therapeutic targets for Alzheimer's disease.

QIAGEN and McGill University partner to drive innovation in microbiome research

Three-year collaboration to pioneer new insights in microbial sciences and health applications.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top